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resumo 
 
 
A Doença de Alzheimer (DA) é uma doença neurodegenerativa, caracterizada 
pela presença de placas senis extracelulares, tranças neurofibrilares 
intracelulares e perda sináptica.  
A neuroinflamação tem sido associada com algumas doenças 
neurodegenerativas, tal como a DA. Na DA, a produção e agregação 
aumentada do péptido Aβ, tem um papel fundamental na activação do 
processo inflamatório, que pode ser importante nas fases iniciais da doença, 
devido à remoção de Aβ e à proteção do cérebro. No entanto, uma inflamação 
crónica leva a um aumento de mediadores inflamatórios como são as citocinas, 
libertadas por microglia activada, astrócitos e neurónios. A produção excessiva 
de componentes inflamatórios promove alterações tanto na expressão como 
no processamento da proteína percursora amilóide (APP), levando a uma 
maior acumulação de Aβ e fosforilação anormal da proteína tau. Isto resulta 
em efeitos neurotóxicos, dano irreversível e perda neuronal. 
A inflamação crónica é uma característica da DA, no entanto pouco se sabe 
sobre os efeitos de algumas quimiocinas na sua patogénese. Assim, o 
principal objectivo desta tese foi o estudo do impacto da IL-8 e da MCP-1 na 
apoptose, APP e tau. Ambas as quimiocinas em estudo resultaram em 
pequenas alterações ao nível da citotoxicidade de células SH-SY5Y 
diferenciadas, tendo sido apenas observado um aumento significativo da 
apoptose para MCP-1 à concentração mais elevada. Relativamente ao 
processamento de APP, não foram observadas alterações significativas, no 
entanto alguma tendência para aumentar a diferentes concentrações e 
períodos foi obtida tanto para a IL-8 como para a MCP-1. Ao nível da tau e 
outras proteínas associadas ao citoesqueleto, foi possível observar uma 
tendência de aumento do resíduo fosforilado Ser396 às concentrações mais 
elevadas assim como alterações na actina e tubulina, com um aumento da α-
tubulina acetilada. Este efeito pode ser traduzido em alterações na arquitetura 
e sobrevivência neuronal. Assim sendo, estudos adicionais podem contribuir 
para uma melhor compreensão do modo de ação destas quimiocinas na 
patogénese da DA. 
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abstract 
 
Alzheimer’s Disease (AD) is a neurodegenerative disorder neuropathologically 
characterized by the presence of extracellular senile plaques, intracellular 
neurofibrillary tangles and synaptic loss.  
Neuroinflammation has been associated with some neurodegenerative 
diseases, such as AD. In AD, increased Aβ production and aggregation, have a 
fundamental role in the activation of the inflammatory process. In turn, this 
could be fundamental in the early stages of this pathology, regarding the Aβ 
clearance and brain protection. However, chronic inflammation leads to an 
increase of the inflammatory mediators, such as cytokines, released by 
activated microglia, astrocytes, and neurons. The excessive production of these 
inflammatory components promotes alterations in both amyloid precursor 
protein (APP) expression and processing, stimulating the increase of Aβ 
accumulation and abnormal tau phosphorylation. This results in neurotoxic 
effects, irreversible damage and neuronal loss. 
Chronic inflammation is a feature of AD however, little is known about the 
effects of some chemokines on its pathogenesis. Thus, the main aim of this 
thesis was to study the impact of the interleukin-8 (IL-8) and monocyte 
chemoattractant protein-1 (MCP-1) on apoptosis, APP and tau. The both 
studied chemokines resulted in small alterations regarding the cytotoxicity on 
SH-SY5Y differentiated cells, being a significant increase in apoptosis observed 
only for the MCP-1 at the highest concentration. For the APP processing no 
significant differences were obtained, although a tendency to increase at 
different concentrations and periods was registered for both IL-8 and MCP-1. 
With respect to tau and other cytoskeleton-associated proteins, it was possible 
to observe a tendency to increase in the phosphorylated residue (Ser396) at 
the higher concentrations, as well as alterations on actin and tubulin with an 
increase on acetylated-α tubulin. This effect can be translated by neuronal 
architectural and survival alterations. Therefore additional studies could 
contribute to a better understanding of the way that these chemokines act on 
AD pathogenesis. 
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1 – Introduction 
 
1.1 – Neurodegenerative Diseases 
Neurodegenerative diseases (ND) are multifactorial debilitating disorders of the nervous 
system that affect approximately 30 million individuals worldwide. Alzheimer’s (AD), 
Parkinson’s (PD), Huntington’s (HD) diseases and amyotrophic lateral sclerosis (ALS) are 
a ND group characterized by separate etiologies with distinct morphological and 
pathophysiological features. Abnormal protein dynamics with defective protein 
degradation and aggregation; oxidative stress and free radical formation like the reactive 
oxygen species (ROS); impaired bioenergetics and mitochondrial dysfunction as well as 
exposure to metal toxicity, are among the etiology factors of ND (Figure 1) and also 
strongly associated with ageing [1]. 
All these factors will contribute to the neurodegenerative process by a slow and 
progressive dysfunction and loss of neurons in the central nervous system, that can 
ultimately lead to dementia [2]. 
 
 
  
Figure 1 – Factors associated with neurodegenerative diseases. Genetic factors/age and 
environmental factors as part of the etiology of neurodegenerative diseases (adapted from [1]). 
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Dementia is an overall term for diseases and conditions characterized by a decline in 
memory or other thinking skills, that affects a person’s ability to perform everyday 
activities [3]. There are many different types of dementia although some are far more 
common than others. Alzheimer’s disease is the most common type of dementia, 
corresponding to about 60-70% of the cases, while vascular dementia (VaD) is the second, 
with about 20% of all cases [4–6]. 
Studies based on epidemiological data acquired over recent years suggested that 
24.2 million people live with dementia and 4.6 million new cases arise every year. The 
prevalence rates for Alzheimer’s disease also rise exponentially with age, increasing 
markedly after 65 years old. Given that both established and developing nations are rapidly 
aging, the frequency is expected to double every 20 years until 2040 [7]. 
1.2 – Alzheimer’s Disease (AD) 
In 1907, the German psychiatrist and neuropathologist Alois Alzheimer described the case 
of a woman who presented a relatively rapidly deteriorating memory along with 
psychiatric disturbances. AD is today, as it was then, a relentless neurologic deterioration 
(Figure 2) accompanied by a massive neuronal loss [5]. It is characterized by progressive 
cognitive decline usually beginning with impairment in the ability to form recent 
memories, but inevitably affecting all intellectual functions, leading to complete 
dependence for basic functions of daily life and premature death [7]. Behavioral and 
psychiatric symptoms, clustered into agitation/ aggression, mood disorders, and psychosis, 
may occur along the disease’s progression [8]. 
 
 
 
  
 
 
 
 
 
 
Figure 2 – Massive cell loss in the Alzheimer’s brain. (A) The cortex (blue contour) shrivels up, 
damaging areas involved in thinking, planning and remembering; (B) Shrinkage is especially 
severe in the hippocampus (white circles), an area of the cortex that plays a key role in the 
formation of new memories and (C) Ventricles (marked by the white circles) that are fluid-filled 
spaces within the brain, grow larger (adapted from http://www.alz.org/braintour). 
A B C 
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1.2.1 – Etiology of AD 
 
Even though the etiological mechanisms underlying the neuropathological changes in 
Alzheimer’s disease (AD) remain unclear, there are a large number of factors that has been 
associated with the increased risk of AD, namely age, genetic and environmental factors 
[7].  
o Age 
Age represents, by far, the single greatest risk factor in the etiology of AD. Indeed, in 
genetically-predisposed individuals, the disease occurs around the age of 50. Therefore, 
regardless of whether one is genetically predisposed or not, aging is an essential factor in 
AD, strongly suggesting that an age-related process is involved in the development of the 
disease [5]. The incidence of AD increases with age and the majority of the individuals 
with the disease are at age 65 or older. In terms of the likelihood for developing 
Alzheimer’s, it doubles about every five years after the age of 65 and above 85 the risk 
reaches nearly 50 percent [7].  
o Family History 
Following advanced age, family history is the second strongest risk factor for Alzheimer’s 
disease. AD is considered to be a genetically dichotomous disease present in two forms: 
early-onset familial cases, EO-FAD (< 65 years old), usually characterized by Mendelian 
inheritance, and the most common form of the disease defined as late-onset, LOAD (> 65 
years old), with no consistent mode of transmission. The “sporadic” AD is strongly 
influenced by genetic variants combined with life exposure factors, while EO-FAD is 
mainly caused by rare, fully penetrant mutations in three different genes, APP and 
Presenilins (listed in the Table I). Therefore those who have a parent, brother, sister or 
children with Alzheimer’s are more likely to develop the disease, with an additional 
increased risk if more than one family member has the illness. When diseases tend to run 
in families, either heredity (genetics) or environmental factors, or both, may play a key role 
[9]. 
o Genetics (heredity) 
Rare mutations in APP (Amyloid Precursor Protein), PSEN1 (Presenilin 1), and PSEN2 
(Presenilin 2) virtually guarantee EO-FAD, which represents approximately 5% of the 
Alzheimer’s disease patients. To date, 24 mutations have been reported for APP, 185 for 
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PSEN1, and 14 for PSEN2. EO-FAD mutations in these three genes leads to a common 
molecular phenotype, which represents an increase in the ratio of the Aβ42:Aβ40, being the 
Aβ1-42 more willing to form aggregates and more toxic than the Aβ1-40. One mutation in 
APP raises all species of Aβ and several others, resulting in amino acid substitution within 
the Aβ domain and leading to increased aggregation of Aβ (Table I). However, most EO-
FAD mutations increase the Aβ42:Aβ40 ratio. The relative escalation in Aβ42 promotes the 
aggregation of the peptide into oligomers and ultimately amyloid fibrils, which have 
neurotoxic properties [9].  
 
 
 
 
Whereas EO-FAD is characterized by classic Mendelian inheritance usually in an 
autosomal-dominant manner, for LOAD, it is observed a genetically complex pattern of 
inheritance in which genetic risk factors work together with environmental factors and life 
exposure events to determine lifetime risk for AD. 
The ApoE (Apolipoprotein E) polymorphic alleles, on chromosome 19q13, are the 
main genetic determinants of Alzheimer’s disease risk in late-onset cases: individuals 
carrying the ε4 allele (ApoE ε4 allele) are at an increased risk of AD (20-25% of the 
Alzheimer’s cases) compared with those carrying the ε3 allele (APOE ε3 allele), whereas 
the ε2 allele (ApoE ε2 allele) decreases the risk of the disease [9]. 
ApoE bind to several cell-surface receptors to deliver lipids, and also to 
hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to 
synaptic dysfunction and neurodegeneration in Alzheimer’s disease. ApoE isoforms 
differentially regulate Aβ aggregation and clearance in the brain, and have distinct 
functions in regulating brain lipid transport, glucose metabolism, neuronal signaling, 
neuroinflammation and mitochondrial function [9,10]. 
Gene Protein Chromosome Mutations Molecular phenotype 
APP Amyloid β (Aβ) 
protein precursor 21q21 24 (duplication) 
Increased Aβ42/Aβ40 ratio 
Increased Aβ production 
Increased Aβ aggregation 
PSEN 1 Presenilin 1 14q24 185 Increased Aβ42/Aβ40 ratio 
PSEN 2 Presenilin 2 1q31 14 Increased Aβ42/Aβ40 ratio 
Table I - Early-onset familial Alzheimer’s disease (EO-FAD) genes and their pathogenic effects 
[9]. 
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Other genes exhibit genome-wide significance for the association with LOAD: CD33, 
GWA-14q31.2, ATXN1, CLU, PICALM, CR1, BIN1, ABCA7, MS4A6E/MS4A4E, CD2AP 
and EPHA1 [8,9]. 
 According to amyloid (or Aβ hypothesis), neurodegenerative processes results from an 
imbalance between Aβ production and Aβ clearance, suggesting that other genes involved 
in these pathways (Table II) might also turn out to be risk factors [7]. 
 
o Environmental and Other Factors  
The diet is one of the most important modifiable environmental factors associated with the 
risk of Alzheimer’s disease. The study performed by Gu and colleagues [11] indicated that 
higher consumption of certain foods (salad dressing, nuts, fish, tomatoes, poultry, 
cruciferous vegetables, fruits, dark and green leafy vegetables) and lower of others (high-
fat dairy, red meat, organ meat, and butter) may be associated with a decreased risk of 
developing AD via a more favorable profile of nutrients (i.e. lower ingestion of saturated 
fatty acids and higher ingestion of polyunsaturated fatty acids, vitamin E and folate). This 
is a characteristic of a composite dietary pattern such as the Mediterranean diet [7], that 
when combined with regular physical activity (compared with none or minimal), is 
associated with a significant reduction in the risk of AD. Exercise can enhance learning in 
both young and aged people, activate brain plasticity mechanisms, remodel neuronal 
circuitry in the brain, promote brain vascularization, and stimulate neurogenesis. It may 
Gene Main alteration Presumed mechanism 
Amyloid precursor protein (APP) Mutation Autosomal dominant, mostly 
early onset 
Presenilin 1 (PSEN1) Mutation Autosomal dominant, mostly 
early onset 
Presenelin 2 (PSEN2) Mutation Autosomal dominant, mostly 
early onset 
Apolipoprotein E (ApoE) Common variant Familial and sporadic, late onset 
Sortilin-related receptor, L(DLR class) A   
repeats-containing (SORL1) 
Common variant Familial and sporadic, late onset 
Clusterin (CLU) Common variant Sporadic, late onset 
Phosphatidylinositol binding clathrin 
assembly protein (PICALM) 
Common variant Sporadic, late onset 
Complement componente (3b/4b) receptor 
1 (CR1) 
Common variant Sporadic, late onset 
Bridging integrator 1 (BIN1) Common variant Sporadic, late onset 
Table II - Gene variants associated with Alzheimer’s disease [7]. 
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likewise increase neuronal survival and resistance to brain insults, increase levels of brain 
derived neurotrophic factor, mobilize gene expression profiles, that were predicted to 
benefit brain plasticity, and reduce levels of C-reactive protein (CRP) and interleukin-6 
(IL-6), which are two inflammatory markers [7]. Also, individuals with intellectually 
enriched lifestyles, such as those with high educational and/or occupational attainment, 
have a reduced risk for AD pathology. Additionally, there is evidence for a protective role 
of leisure activities in dementia development, by improving lipid metabolism and mental 
stimulation [5,7]. 
There are other factors that modify the risk for Alzheimer’s disease development 
such as cardiovascular diseases, sex or history of diabetes, hypertension, depression, 
smoking, obesity, dyslipidemia or traumatic head injury [5,7,12,13]. 
1.2.2 – Pathogenesis of AD 
 
The major pathological features of Alzheimer’s disease (AD) are the extracellular 
accumulation of β-amyloid (Aβ) peptide in the senile plaques (SP) (Figure 3A) and the 
intracellular accumulation of abnormally phosphorylated tau protein (Figure 4B) as 
neurofibrillary tangles (NFT) (Figure 3C) [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Pathological features of Alzheimer’s disease (AD). (A) Senile plaques (SP) are 
demonstrated in Bielshowsky silver impregnation; (B) Immunohistochemical stain for 
phosphorylated tau (monoclonal antibody AT8 which recognizes phosphorylation at residues 202 
and 205) shows numerous distended neurites in a classic neuritic plaque (a senile plaque subtype) 
and (C) Neurofibrillary tangles (NFT), as seen on the Bielshowsky silver stain, were initially 
characterized by Alzheimer (adapted from [5]). 
A B C 
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o APP and Aβ genesis 
Amyloid Precursor Protein (APP) is one of the three members of a small gene family, 
which includes the Amyloid Precursor Like Protein (APLP) 1 and APLP2 (human), but 
only APP contains sequence encoding the Aβ domain [14]. It is a ubiquitously expressed 
type I membrane glycoprotein that is encoded by a single gene on the chromosome 21q21 
and multiple isoforms exist resulting from alternative splicing. The predominant transcripts 
are APP695, APP751 and APP770. APP is expressed in many cells and tissue types including 
endothelia, glia and neurons. Whereas APP695 is the predominant isoform in neuronal cells, 
APP751 and APP770 are predominantly expressed in peripheral tissues. 
From the proteolytic processing of the APP, derives the Aβ peptide. APP can be 
cleaved by two different pathways (Figure 4). In amyloidogenic pathway, APP is 
processed by β-secretase that generates the soluble fragment sAPPβ and a membrane 
associated C terminal fragment consisting of 99 amino acids (C99). C99 is a substrate for 
γ-secretase, leading to the release of the APP intracellular domain (AICD) and generating 
Aβ peptide, which aggregates and fibrillates to form amyloid plaques in the brain [15]. 
Alternatively, in the non-amyloidogenic pathway APP is sequentially cleaved by α-
secretase and γ-secretase. α-secretase originates the soluble APP-fragment sAPPα and a 
membrane-associated C-terminal fragment consisting of 83 amino acids (C83). APP C83 is 
further cleaved by γ-secretase to release a P3 peptide and the AICD, both of which are 
rapidly degraded. 
Figure 4 – APP processing and Aβ accumulation. Mature APP (center, inside dashed box) is 
metabolized by two competing pathways, the α-secretase or non-amyloidogenic pathway that 
generates sAPPα and C83 (also known as CTFα; left) and the β-secretase or amyloidogenic 
pathway that generates sAPPβ and C99 (right) (taken from [16]). 
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Aβ overproduction and aggregation into SP, appear central to the clinical 
manifestation of Alzheimer’s disease, both in sporadic and familial early-onset cases [6]. 
Aggregates of the Aβ peptide accumulate in the plaques and vessel walls [2] and of the 
several Aβ species found in AD, Aβ42 rather than Aβ40, represents the predominant form of 
the peptide deposited in SP, whereas Aβ40 is more likely involved in vascular amyloid 
deposition [6]. 
o Tau and NFTs formation 
Neurofibrillary tangles, the other major well-recognized pathological hallmark of 
Alzheimer’s disease, accumulates early in AD brains. Caused by abnormal 
hyperphosphorylation of tau by the putative kinases, glycogen synthase kinase-3β (GSK-
3β) and cyclindependent kinase 5 (cdk5), NFT accumulate intracellularly in the neuronal 
cytoplasm [15]. Tau, is the most abundant microtubule-associated protein that interacts 
with cytoskeleton proteins (such as actin) promoting microtubule assembly and stability, as 
well as regulating the intracellular vesicles and organelle traffic. On the other hand, 
hyperphosphorylated tau (p-tau) displays a strong tendency to abnormally aggregate, 
leading initially to paired helical filaments formation and then to larger NFT. Microtubular 
and cytoskeletal instability due to p-tau and NFT formation, leads to impaired axonal 
transport to presynaptic and postsynaptic terminals, causing energy and neuronal 
nutritional depletion at these sites. This in turn results in neuronal degeneration [6]. 
 
The most influential theory to explain the pathogenesis of AD has been the 
“Amyloid Cascade Hypothesis” (ACH) first formulated in 1992. The ACH proposes that 
the deposition of Aβ is the initial pathological event in AD, which leads to the formation of 
senile plaque, then to neurofibrillary tangles, death of neurons and ultimately dementia. 
Nevertheless, there are observations that are difficult to reconcile with this hypothesis, thus 
a modification of the original ACH was proposed to better explain the pathogenesis of the 
AD [17,18]. In this modified hypothesis (Figure 5), the essential trigger to the development 
of AD is brain ageing and the associated risk factors such as head trauma, vascular disease, 
and systemic disease that are referred to as the “allostatic load”. These factors exacerbate 
processes leading to cell death. Genetic factors, rather than initiating disease, indirectly 
influence the formation and composition of peptides, formed when neurons degenerate. As 
neurons degenerate, various proteins are upregulated leading to the formation of 
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extracellular Aβ deposits and intracellular tau phosphorylation, latter resulting in the NFT 
development. These reaction products may be toxic and initiate a further phase of 
secondary degeneration that accelerates the neuronal loss leading to dementia [17]. 
Significant neuronal loss occurs in the cholinergic nuclei of the basal forebrain, which 
projects widely to cortical areas and accounts for the observed cholinergic 
neurotransmission deficits that contribute, in part, to memory decline [6].  
 
 
 
 
 	  
 
 
 
 
 
 
1.2.3 – Diagnosis of AD 
 
In 1984 representatives from the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer Disease and Related Disorders Association 
(NINCDS-ADRDA) developed a uniform set of criteria to enable clinicians and 
researchers to maintain consistency in the Alzheimer’s disease diagnosis. These included 
aspects of medical history, clinical examination, neuropsychological testing, and laboratory 
assessments. However, these NINCDS-ADRDA criteria were recently updated due to the 
advances in neuropsychological assessment, brain imaging and the neuropathological, 
biochemical and genetic understanding of the disease. The growing use of brain imaging 
and cerebrospinal fluid (CSF) biomarkers, aid in the specificity and sensitivity of the 
diagnosis and thus are considered in the updated diagnostic criteria, especially when used 
for clinical research [7].  
Figure 5 - A modification of the “Amyloid Cascade Hypothesis” (ACH) (taken from [17]). 
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Alzheimer’s disease diagnosis requires clinical evidence of memory loss and 
impairment of at least one other cognitive domain, with evidence of disturbance in social 
or occupational function [5]. The global indices of cognitive performance and global 
functional status could be obtained using both the Mini-Mental State Examination 
(MMSE) and the Clinical Dementia Rating (CDR) [19].  
The neuroimaging techniques such as Magnetic Resonance Imaging (MRI) and 
Positron Emission Tomography (PET) may potentiate the diagnosis of AD [20]. 
Neuropathological studies have documented an abundance of NFT and significant neuronal 
loss in the hippocampus and entorhinal cortex of AD patients. Therefore, these have been 
the areas frequently targeted by imaging techniques [21,22]. 
MRI is useful for neuroimaging examination for Alzheimer’s disease because it 
allows an accurate measurement of the 3-dimensional (3D) volume of the brain structures, 
especially the size of the hippocampus and related regions (Figure 6A) [23]. PET has been 
employed in many AD studies to examine the regional cerebral metabolic rate for glucose 
(rCMRGLc) using 18F-2-deoxy-2-fluoro-D-glucose (FDG) as a marker. Reduction of 
glucose metabolism, observed on PET in the bilateral temporal parietal regions and in the 
posterior cingulate (Figure 6B), is the most commonly described diagnostic criteria for 
AD. PET imaging using 11C-labeled PIB {2-[4’-(methylamino) phenyl]-6-
hydrobenzothiazole} ligand has also been one of the major diagnostic tools more recently 
developed for AD. PIB binds with high affinity and high specificity to fibrillar Aβ in 
neuritic plaques and cerebral amyloid angiopathy (Figure 6C). In AD patients, PIB 
retention is increased in the frontal, parietal, temporal and occipital cortices, and in the 
striatum [21].  
 
 
 
 
 
 
 
 
Figure 6 – Neuroimaging techniques in two representative cases. (A) MRI; (B) FDG-PET; and 
(C) PIB-PET of a normal control (top row) and an Alzheimer’s disease patient (bottom row). MRI: 
Magnetic Resonance Image; PET: Positron Emission Tomography (adapted from [24]). 
A B C 
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Since deposition of β-amyloid (Aβ) peptide is known to precede clinical signs of 
dementia, PIB-PET may facilitate the early detection of amyloid during preclinical AD. 
The cognitively normal elderly people demonstrate substantial PIB retention in the cortex 
by their mid-70s, and this PIB retention is similar in extent to that of patients with mild-to-
moderate AD. Brain amyloid can be assessed based on reductions in the CSF Aβ42 levels 
and increased PIB retention while an elevated CSF tau is thought to be a biomarker of tau-
mediated neuronal injury and neurodegeneration. Decreased FDG uptake on PET in the 
temporoparietal area is a biomarker of AD-related synaptic dysfunction, and brain atrophy 
seen on structural MRI involving the medial temporal lobe is a biomarker of AD-related 
neurodegeneration. Structural MRI is the last biomarker to become abnormal [21,25]. 
 
Different biomarkers for Alzheimer’s disease may potentially be complementary 
in diagnosis and prognosis of AD [20]. Nowadays a definitive diagnosis can only be made 
on histological examination of the brain at autopsy [5]. Thus the identification of 
individuals with preclinical AD before the development of cognitive deficits and 
concomitant neuronal loss is fundamental to a timely therapeutic intervention [21]. 
There are two basic types of biomarkers in Alzheimer’s disease: (a) trait biomarkers 
that define a risk state for AD but do not necessarily indicate that the disease is present and 
(b) state biomarkers that are indications of pathological changes of AD [26].  
Genetic biomarkers, such as autosomal dominant AD-causing mutations and the 
Apolipoprotein E ε4 (ApoE ε4), and other risk polymorphisms are examples of trait 
biomarkers. State biomarkers indicate the presence and/or the severity of AD and they can 
be used for diagnosis, staging, or outcomes assessment. The principal state biomarkers 
include atrophy on MRI; reduced metabolism on FDG-PET; and more recently, amyloid 
deposition on amyloid imaging and changes in CSF levels of total tau (t-tau), 
hyperphosphorylated tau (p-tau), or Aβ1–42 (Figure 7) [26].  
The cortical axonal degeneration that occurs in AD brains, results in increased CSF 
levels of t-tau, which predicts a rapid cognitive decline. Regarding the CSF levels of p-tau 
protein, they are the most specific finding suggesting an ongoing AD process in the brain 
and are also increased [27]. CSF Aβ1-42 levels are commonly decreased in patients with 
Alzheimer’s disease, possibly because it is the main component of AD plaques, which may 
function as sinks or traps, thus decreasing the amount of Aβ1-42 cleared from the brain to 
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the cerebrospinal fluid (Table III) [21].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The routine diagnosis of AD based on cerebrospinal fluid has several drawbacks: 
lumbar puncture and collection of CSF is an invasive treatment with potential side effects, 
screening of patients is often difficult and follow-up analysis of the same patient over 
several years is problematic. Thus, recent researches have been focusing in the search for 
biomarkers in other body fluids, such as blood, in order to diagnose AD. However, it is still 
unknown how the concentration of analytes in the blood, more precisely in plasma, directly 
correlates with pathological changes in the AD brain [29]. 
ALZHEIMER’S DISEASE (AD) 
 
Plasma CSF References 
Aβ42 
 
 [29], [21], [30], 
[25], [31] 
t-tau Less elevated 
 
[29], [31], [32], 
[33], [34], [35] p-tau Less elevated 
 
Figure 7 - Dynamic biomarkers of the Alzheimer’s pathological cascade. β-amyloid peptide 
(Aβ) is identified by cerebrospinal fluid (CSF) Aβ42 or PET amyloid imaging. Tau-mediated 
neuronal injury and dysfunction is identified by CSF tau or fluorodeoxyglucose-PET. Brain 
structure is measured by use of structural MRI. PET: Positron Emission Tomography; MRI: 
Magnetic Resonance Imaging; MCI: Mild Cognitive Impairment (taken from [28]). 
Table III - Fluid biomarkers of Alzheimer’s disease (AD). β-amyloid (Aβ) 42, total tau (t-tau) 
and hyperphosphorylated tau (p-tau) levels in plasma and cerebrospinal fluid (CSF). Up arrow = 
Increase; and Down arrow = Decrease.  
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The pathogenic process of AD probably starts decades before clinical onset of the 
disease. During this preclinical period, there is a gradual neuronal loss and the first 
symptoms, most often impaired episodic memory, appear at a certain threshold. This 
clinical phase is often designated as mild cognitive impairment (MCI) [33]. There are two 
terminological systems to identify AD stages (Table IV). The International Work Group 
identifies at-risk cognitively normal populations, prodromal AD, and AD dementia. While 
the approach of the National Institute on Aging/ Alzheimer’s Association describes 
preclinical AD, MCI of the AD type (with intermediate or high likelihood of AD), and AD 
dementia (with intermediate or high likelihood of AD) [26,32].  
 
 
 
 
The development of validated biomarkers for AD is essential to improve its 
diagnosis and accelerate the development of new therapies. Biochemical and neuroimaging 
markers could facilitate diagnosis, predict AD progression from a pre-AD state of MCI, 
and be used to monitor efficacies of disease-modifying therapies [19].  
Other biomarkers associated to relevant processes for AD, such as those involved in 
inflammation, are also being tested due to the possible link with the disease pathogenesis. 
 
Features International Work 
Group criteria 
National Institute on Aging/Alzheimer´s 
Association criteria 
Normal cognition; intact ADLs; 
biomarker evidence of AD 
At-risk state with AD 
pathology 
Preclinical AD 
Abnormal cognition; normal 
ADLs; biomarker evidence of AD 
Prodromal AD MCI due to AD; intermediate likelihood: 
one biomarker present (Aβ or neuronal 
injury); high likelihood: two biomarkers 
present (Aβ plus neuronal injury) 
Abnormal cognition; abnormal 
ADLs; biomarker evidence of 
AD 
AD dementia AD dementia; intermediate likelihood: one 
biomarker present (Aβ or neuronal injury); 
high likelihood: two biomarkers present (Aβ 
plus neuronal injury) 
Table IV – Classification of the Alzheimer’s disease stages. Aβ: amyloid-β; AD: Alzheimer’s 
disease; ADLs: activities of daily living; MCI: mild cognitive impairment (adapted from [26]). 
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1.3 – Inflammation in AD 
Inflammation is a body response to eliminate the initial cause of cell injury as well as 
necrotic cells and tissues resulting from original insult. The cells responsible for the 
inflammatory reaction are microglia, astrocytes, and neurons that when activated produce 
high levels of inflammatory mediators such as pro-inflammatory cytokines and 
chemokines. Prostaglandins, leukotrienes, thromboxanes, coagulation factors, free radicals 
as reactive ROS and nitric oxide (NO), complement factors, proteases and protease 
inhibitors, and C-reactive protein (CRP) are also produced by them [6,12,36]. Brain 
inflammation is a pathological hallmark of Alzheimer’s disease. Robust evidences of 
disturbances in inflammation and immune pathways in the disease is strongly associated 
with increased levels of acute-phase proteins and pro-inflammatory cytokines in blood, 
CSF and post-mortem brain tissue of AD patients [37]. 
An acute insult is typically short-lived and unlikely to affect the long-term neuronal 
survival. Moderately active microglia is thought to perform beneficial functions, such as 
scavenging neurotoxins, removing dying cells and cellular debris, and secreting trophic 
factors that promote neuronal survival [38].  
In contrast, chronic neuroinflammation is a long-standing and often self-
perpetuating neuroinflammatory response that persists long after an initial injury or insult. 
Chronic neuroinflammation includes long-standing activation of microglia and subsequent 
sustained release of inflammatory mediators. This works to perpetuate the inflammatory 
cycle, activating additional microglia, promoting their proliferation, and resulting in further 
release of inflammatory factors, which in turn leads to elevated levels of several cytokines 
[38].  
Signs of chronic inflammation occur in pathologically susceptible regions in AD 
brains as a response to Aβ peptide deposition and NFT formation. One hypothesis is that 
both Aβ plaques and tangles stimulate a chronic inflammatory reaction. In turn, 
inflammatory mediators, enhance APP production and the amyloidogenic processing of 
APP to induce increased Aβ42 peptide production. These circumstances also inhibit the 
generation of a soluble APP fragment that has a neuroprotective effect. On the contrary, 
Aβ induces the expression of pro-inflammatory cytokines, such as interleukins (IL)-1β, IL-
6, and tumor necrosis factor (TNF)-α in glial cells, leading to a vicious cycle [12,38]. 
Therefore, the neuroinflammatory process triggered by Aβ42, plays a central role in the 
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neurodegenerative process. This inflammatory process leads to both synaptic and neuronal 
damage as well as further inflammatory cell activation [6,29]. The activation of microglia 
results in a phagocytic phenotype and the release of inflammatory mediators that promote 
the inflammatory state [38]. 
Neurodegeneration and neuroinflammation can result in changes of the central 
nervous system (CNS) proteins (for example, Aβ peptide) or inflammatory mediators 
across the Blood Brain Barrier (BBB). These CNS-derived proteins and mediators may 
induce systemic immune reactions and/or recruit lymphocytic cells into the CNS. Other 
than CNS resident cells, blood-derived cells can also be blamed for inflammatory response 
and seem to accumulate in the AD brain due to the expression of chemokine receptors [12] 
(Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Neuroinflammation process in AD. During Alzheimer’s disease, Aβ molecules 
accumulate and forms mature Aβ plaques (SP). In response to the deposition of Aβ and the release 
of chemoattractants from damaged neurons, activated astrocytes, microglia, and macrophages 
release pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. These inflammatory 
compounds amplify the pro-inflammatory response, producing neurotoxic effects. Adhesion 
molecules and chemokines are also produced, being responsible for the recruitment of peripheral 
immune cells (taken from [39]). 
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o Interleukins in AD 
Interleukins are an important class of inflammatory cytokines in many organs and tissues. 
They direct the inflammatory response within the CNS by activating several intracellular 
signalling pathways within multiple CNS cell types, as well as coordinating signalling 
between neurons and astrocytes. Several cytokines thought to be important in AD 
pathogenesis have been found upregulated in vulnerable areas in patient’s brains [6,40]. 
The most potent cytokines are interleukin-1α (IL-1α), IL-1, IL-6 and TNF-α [36]. 
Swardfager and collaborators [41] performed a meta-analysis to study the cytokines 
present in AD. Obtained data revealed higher peripheral concentrations of IL-6, TNF-α, 
IL-1β, transforming growth factor-β (TGF-β), IL-12 and IL-18 and higher TGF-β 
concentrations in the CSF. 
Further, it was also shown that interleukin-1 receptor antagonist (IL-1ra), IL-6 and 
IL-10 were significantly associated with ventricular volume in AD [42]. Of note abnormal 
cytokine levels can also impact on APP, for instance, inflammatory cytokines such as IL-
1β, IL-6, TNFα, or interferon (IFN) gamma can augment APP expression and Aβ 
formation [8]. 
There is a feedback signalling loop between Aβ and IL-1β: Aβ can induce the 
production of IL-1β, whose presence greatly increases the secretion of the cytokine IL-6 
and chemokine IL-8 in response to Aβ by astrocytes. On the other hand, both IL-1α and 
IL-1β upregulate the expression of APP, potentially enhancing the production of Aβ. 
However, IL-1β may also activate the non-amyloidogenic pathway [38].  
IL-18 likewise, significantly elevated in brain specimens from AD patients, can 
increase the amyloid plaque formation by inducing the expression of PSEN1 and the β-site 
APP-cleaving enzyme 1 (BACE1), involved on APP amyloidogenic processing. 
Additionally, IL-18 can increase levels of Cdk5/p35 and GSK-3 kinases, leading to tau 
hyperphosphorylation [43]. 
o Chemokines in AD 
Chemokines are a family of conserved chemotactic cytokines able to induce the migration 
of several leukocyte subpopulations into damaged tissues. Chemokines are classified into 
four families: CC, CXC, CX3C and C [44], and in the adult brain, microglia and astrocytes 
are believed to be the main source of chemokine production. The CNS has been shown to 
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produce chemokines in response to several inflammatory and disease conditions, including 
Alzheimer’s disease [45]. 
Exposure of microglial cells to Aβ causes their activation and leads to the 
production not only of pro-inflammatory cytokines and but also of chemokines, such as 
macrophage inflammatory protein-1α (MIP-1α), monocyte chemoattractant protein-1 
(MCP-1) and IL-8. Astrocytes, the most common cells in the brain, can also be activated 
by Aβ peptides to synthetize various pro-inflammatory molecules similar to those 
produced by microglia [44]. 
In particular, MCP-1 (also named CCL2) is produced by microglial cells and 
stimulates astrocytes, which together participate in the degradation of Aβ peptide. 
Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe 
AD patients when compared with controls. More, evidences indicate that plasma MCP-1 
levels could serve as a biomarker to monitor inflammatory process of AD [46]. Porcellini 
and colleagues [47] proposed that, decreased levels of peripheral MCP-1 along with 
increased CSF concentration of this chemokine in AD, may suggest impaired MCP-1 
turnover between these two compartments. 
Besides MCP-1, reactive astrocytes have been shown to secrete other pro-
inflammatory mediators such as RANTES (regulated on activation, normal T-cell 
expressed and secreted) or CCL5 in response to stimulation with Aβ42. In turn, both 
chemokines attract microglial cells, whose further expression of pro-inflammatory 
products, leads to additional neuronal damage [44]. 
Further, both CC chemokines, are found on endothelial cells, glia and neurons 
throughout the brain, suggesting important functions for this inflammatory superfamily in 
the CNS. RANTES could be correlated with Th1 (helper T cell) responses, since it is 
thought to promote leukocyte infiltration in sites of inflammation and activate T cells. 
MCP-1 however, promotes attraction and activation of monocytes, activates T cells, NK 
cells (Natural Killer cells), and basophils, playing a key role in trans-endothelial migration 
of inflammatory cells [43]. 
IL-8, a chemokine produced by macrophage and other cell types in response to pro-
inflammatory mediators such as Aβ, could be important for the recruitment of activated 
microglia into sites of damaged brain. CXCR2, an IL-8 receptor, has been localized in 
dystrophic neurites (defined as thickened or irregular neuronal processes), suggesting that 
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IL-8 mediates glial interactions with neurons thereby contributing to neuronal damage. IL-
8 was significantly increased in the CSF of AD compared to control individuals [48], 
whereas plasma levels in late-onset AD did not differ significantly from controls. In 
contrast, an independent and negative relationship between plasma IL-8 levels and MCI 
and AD patients was showed by Kim et al [46]. Mariani et al [44], showed that CSF levels 
of both MCP-1 and IL-8 were higher in patients with MCI and AD. 
In a study performed by Ray et al [49], a group of plasma proteins, including many 
cytokines and chemokines such as IL-8 and RANTES were proposed to differentiate AD 
patients from controls. More recently Soares and colleagues [50] showed that some of 
those proteins could be detected by bead-based multiplex technology, suggesting a plasma-
based AD signature that may be a useful screening tool.  
Table V summarizes the data obtained for some cytokines in AD patients. 
 
 
 
Cytokines Plasma/ Serum CSF AD brains References 
In
te
rle
uk
in
s 
IL-1β =↑ ↑ ↑ 
[51], [52], [53], 
[54], [42] 
IL-18 =↑ ↑ =↑ 
[55], [56], [57], 
[58] 
IL-6 =↑ ↓↑ ↑ 
[51], [52], [53], 
[59], [60], [61] 
TNF-α ↓↑ = ↑ [62], [63], [64] 
IFN-γ = = --- [65], [61] 
C
he
m
ok
in
es
 IL-8 =↓ ↑ ↑ [42], [66], [46] 
MCP-1 (CCL2) =↓ =↑ ↑ 
[53], [42], [46], 
[67], [68], [63] 
RANTES (CCL5) ↑ --- ↑ [69], [70], [43] 
Table V – Examples of cytokines levels in Alzheimer’s disease (AD). Interleukins and 
chemokines levels in plasma, cerebrospinal fluid (CSF) and AD brains. IL: interleukin; TNF: tumor 
necrosis factor; IFN: interferon; MCP: monocyte chemotactic protein; RANTES: regulated on 
activation, normal T cell expressed and secreted. Up arrow = Increase; Down arrow = Decrease; 
Equalaty symbol = Unaltered; and Dashed = No information.  
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The presence of inflammatory molecules is likely to be a very early event in AD 
pathogenesis, preceding the disease clinical onset. However, it has been proposed that their 
chronic production in advanced Alzheimer’s disorder could be harmful and contributes to 
neuronal death [44]. This may be related with abnormal APP processing and tau 
phosphorylation in AD (Table VI). 
MCP-1 overexpression was shown to induce microgliosis and enhance Aβ deposits 
by reducing their clearance by increasing Apolipoprotein E (ApoE) expression levels. As 
mentioned, Aβ aggregation promotes diffuse plaque formation and is associated with 
neuronal death and consequently cognitive impairments [71,72]. By contrast, MCP-1 also 
enhances Aβ uptake by microglia, which leads to an increase in oligomerized Aβ species in 
both intracellular and extracellular fractions. Microglia-induced Aβ internalization occurs 
through a nonsaturable, fluid phase macropinocytic mechanism, that is dependent on actin 
and tubulin dynamics of the cellular cytoskeleton. Therefore, this suggests that MCP-1 
may prominently activate cytoskeletal dynamics as a part of its chemotactic signalling and 
thereby affect the Aβ uptake [73].  
 
Cytokines Aβ APP processing 
APP & tau 
Phosphorylation 
References 
In
te
rl
eu
ki
ns
 
IL-1β ↑ Aβ 
↑  sAPPα; ↑ γ-
secretase activity & 
AICD 
↑ APP mRNA; ↓ full-
length APP; ↑ tau 
mRNA and p-tau 
[74], [75], 
[76], [77], 
[78], [79] 
IL-18 ↑ Aβ 1-40 
↑ sAPPβ and BACE 
1 
↑ p-APP and p-tau [80], [81] 
IL-6 --- --- 
↑ APP mRNA                           
↑ p-tau 
[82], [83] 
TNF-α 
↑ Aβ  
deposition 
↑ sAPPβ; ↑ γ-
secretase activity & 
AICD 
↑ APP mRNA                           
↑ p-tau 
[79], [84], 
[85], [86] 
Interferon-γ ↑ Aβ 
↑ γ-secretase activity 
& AICD 
↓ p-tau 
[79], [86], 
[87] 
Table VI – Examples of cytokines effects on Aβ peptide, APP and tau. IL: interleukin; TNF: 
tumor necrosis factor; IFN: interferon; MCP: monocyte chemotactic protein; RANTES: regulated 
on activation, normal T cell expressed and secreted; sAPP: soluble APP fragment; AICD: APP 
intracellular domain; BACE1: β-site APP-cleaving enzyme 1; p-tau: hyperphosphorylated tau. Up 
arrow = Increase; Down arrow = Decrease; and Dashed = No information.  
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Progressive Aβ deposition in the brain, as a cause of inflammation and abnormal 
APP processing, can induce disruption of mitochondrial membrane, resulting in ROS 
production, release of cytochrome c from mitochondria and activation of caspase-
dependent apoptotic pathways and consequently neurodegeneration [90]. 
Cytokines per se can trigger apoptotic processes. As an example, a study performed 
by Thirumangalakudi et al [91], showed that IL-8 is able to induce the expression of the 
pro-apoptotic protein Bim leading to neuronal death. Bim is a part of the pro-apoptotic 
Bcl-2 family of proteins that regulate the apoptosis by controlling the mitochondrial 
permeability [92,93].  
 
In summary, inflammatory mediators such as pro-inflammatory cytokines and 
chemokines are present in brain inflammation and represent a pathological hallmark of the 
Alzheimer’s disease. However, as observed in Table VI, little is known about the role of 
chemokines in AD pathogenesis, namely if these chemokines can affect APP processing 
and tau phosphorylation, as well as their impact on apoptosis. 
Hence, additional studies are needed to improve our knowledge about this field in 
order to discover new possible inflammatory biomarkers candidates for AD diagnosis or 
novel targets for therapeutic intervention.  
C
he
m
ok
in
es
 
IL-8 --- --- --- 
 
MCP-1 
(CCL2) 
↑ Aβ  
deposition           
↑ Aβ  uptake & 
oligomerization 
--- --- [88], [89] 
RANTES 
(CCL5) 
--- --- --- 
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2 – Objectives 
 
Alzheimer’s disease is a complex neurodegenerative disorder characterized by the presence 
of SP and NFT, synaptic loss and consequently neurodegeneration. The Aβ peptide is the 
major constituent of SP and gradual Aβ production and aggregation leads to the activation 
of inflammatory responses, which plays a crucial role in AD progression. 
Inflammatory mediators such as pro-inflammatory cytokines and chemokines are 
highly produced by microglia, astrocytes and neurons, during the inflammatory process 
associated to AD. The initial inflammatory response is beneficial and needed to prevent the 
neurotoxicity caused by the amyloid fragments and to limit the disease progression. 
However, the sustained release of inflammatory mediators works to perpetuate the 
inflammatory cycle, activating additional microglia, promoting their proliferation, and 
resulting in further release of inflammatory factors, leading to elevated levels of several 
cytokines. In an advanced AD phase, due to the persistent activation of microglia, chronic 
neuroinflammation occurs, adding in the neurotoxic effects induced by Aβ and leading to 
neuronal death. In particular, the role of chemokines in AD pathogenesis is unclear. Hence 
the aim of this project was to evaluate how IL-8 and MCP-1 impacts on apoptosis and the 
two main AD-related proteins, APP and tau. 
Therefore, the specific aims included: 
i. Evaluate the IL-8 and MCP-1 cytotoxicity; 
ii. Evaluate the effects of the IL-8 and MCP-1 on the Amyloid Precursor Protein 
(APP) processing; 
iii. Determine the impact of the IL-8 and MCP-1 on tau and other cytoskeleton-
associated proteins. 
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3 – Materials and Methods 
 
3.1 – Cell culture 
All procedures involving cell culture and manipulation were performed using a class II air 
flow cabinet. SH-SY5Y human neuroblastoma cells are originally derived from the cell 
line SK-N-SH, established from a bone marrow biopsy of a neuroblastoma patient. SH-
SY5Y cells cryopreserved in liquid nitrogen (-196ºC) were quickly thawed using a water 
bath at 37ºC, and then collected into a conical tube. The culture medium was added 
dropwise (to avoid cell lysis) and re-suspended to dilute the dimethyl sulfoxide (DMSO) 
present in the cell-freezing medium. The cells were centrifuged at 1000 rpm, for 3 min and 
the supernatant removed. The pellet was re-suspended in minimal essential medium 
(MEM):F12 (1:1) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine 
(200 mM stock solution), sodium bicarbonate, sodium pyruvato and 1% of 
antibiotic/antimycotic mix. The cells were then seeded in a culture plate and medium 
replaced in the next day to remove dead cells. Cells were maintained in an incubator, at 
37ºC with 5% CO2/95% air and 95% humidity and passaged when reached approximately 
70-80% of confluence until submitted to experimental procedure. 
3.1.1 – Differentiation of the SH-SY5Y cell line 
 
An optimization of the SH-SY5Y differentiation protocol was carried on before 
experimental procedures with differentiated cells. For differentiation of SH-SY5Y cell line, 
cells were detached with trypsin from the culture plate, count with a hemocytometer and 
seeded at a density of 5x105 cells/well (6-well plate) or 0.5x105 cells/cm2. Cells were 
maintained in an incubator, at 37ºC with 5% CO2/95% air and 95% humidity, during two 
days in 1% FBS culture medium supplemented with 10 µM of retinoic acid (RA – 20 mM 
stock solution).  
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3.1.2 –Chemokine treatment of SH-SY5Y 
 
To test the effects of the chemokines in SH-SY5Y neuroblastoma cells, the lyophilized 
interleukin-8 (IL-8) and Monocyte Chemoattractant Protein-1 (MCP-1) (Both from BD 
Biosciences) were reconstituted in distilled water, aliquoted and stored at - 80ºC.  
For the experimental procedure, IL-8 and MCP-1 (both with 200 ng/µL stock 
solution) were successively diluted in serum free culture medium, both at the final 
concentrations of 10, 50, 100, 150 ng/mL (Figure 9) and added to the culture cells, for 
different time periods (IL-8: 24 and 48 hours; MCP-1: 6 and 24 hours).  
 
 
 
 
 
 
 
 
 
 
 
3.2 – Cell viability 
Cell viability was determined using the MTT assay. MTT is a colorimetric assay developed 
by Mossman, that measures the reduction of yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase. The MTT 
enters the cells and passes into the mitochondria where it is reduced to an insoluble colored 
(dark purple) formazan product. Since reduction of MTT can only occur in metabolically 
active cells, the level of activity is a measure of cell viability. 
SH-SY5Y cells were seeded at a density of 1x105 cell/well in 24-well plates, 
differentiated and incubated in serum free culture medium with crescent concentrations of 
IL-8 and MCP-1 (10, 50, 100 and 150 ng/ml), during 24 and 48 hours. After this time, the 
culture medium was removed and replaced by 250 µL of serum-free culture medium with 
Cf=150 
ng/mL 
Cf=100 
ng/mL 
Cf=50 
ng/mL 
Cf=10 
ng/mL 
Stock 
Solution 
(200 ng/µL) 
SERIAL DILUTION 
Figure 9 – Representative scheme of the serial dilution. Cf: Final concentration. 
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25 µL of MTT (Cf = 0.5 mg/ml). Cells were then incubated at 37ºC for 4 hours. A negative 
control was included (25 µL of the MTT added to 250 µL of the medium alone). After 
incubation, medium was removed and the formed precipitates (dark purple) dissolved with 
250 µL of 99.9% DMSO by vigorously mixing with a pipette. The solutions from each 
well were transferred to a 96-well plate and the absorbance read at 570 nm in the Infinite 
M200 (Tecan). 
 
3.3 – Samples collection and Immunodetection 
After the appropriated treatments with IL-8 and MCP-1, culture media was collected and 
centrifuged at 300g, 4ºC, during 5 min, to avoid cellular contamination, and then diluted 
with SDS 10%, to a final concentration of SDS 1%. 
Cells were collected with RIPA buffer composed by Sodium Fluoride (NaF), 
Sodium Orthovanadate (NaO) and a protease inhibitor cocktail, using a cell scraper. After, 
cell lysates were sonicated twice, during 5 seconds, to obtain homogenous samples. All 
samples were stored at -20ºC before their preparation for SDS-PAGE. Culture media was 
used for sAPP detection and cell lysates for APP and tau detection. 
3.3.1 – Determination of the protein concentration 
 
For cell lysate protein quantitation the bicinchoninic acid (BCA) protein assay (Pierce), 
based on the use of the BCA, for the colorimetric detection and quantitation of the total 
protein, was used. This method combines the capability of the proteins to reduce Cu2+ to 
Cu+ in an alkaline environment (the biuret reaction). BCA produces a purple color in the 
presence of the reduced Cu+ ion that results from chelation of two molecules of BCA with 
one cuprous ion. These soluble complexes give origin to a purple-colored reaction product, 
which exhibit a strong absorbance at 562 nm.  
The quantitative analyses were performed using 5 µL of the collected cell lysates and a 
standard curve, prepared was described in Table VII. The samples and standards were 
incubated with 200 µL of working reagent (mixture of reagent A with reagent B in the 
proportion of 50:1) and incubated at 37ºC during 30 min. After some minutes (in order to 
cool down the samples), the absorbance was measured at 562 nm in the Infinite M200 
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(Tecan). The I-controlTM software was used for data acquisition. Protein content was 
normalized and samples submitted to SDS-PAGE. 
 
 
 
 
 
 
 
 
 
 
3.3.2 – SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was prepared to 
separate proteins according to their molecular weight and negative charge. The principle of 
the SDS-PAGE relies on the capacity of the proteins to migrate through gel pores when 
submitted to an electrical field. The gel percentage and size depend on the molecular 
weight of the proteins to be separated. As proteins have different electrical charges that 
affect their mobility, SDS is usually added to protein samples and buffers to confer a 
negative charge to all proteins, ensuring their migration toward the positively charged 
anode. SDS is also used in combination with a reducing agent (mercaptoethanol) and 
heated to dissociate proteins before loading on the gel. SDS also breaks up aggregates and 
non-covalently bound multimers.  
Gels comprised two phases: in the top, the non-restrictive large pore called stacking 
gel and in the bottom, the resolving gel with a linear progression of acrylamide 
concentrations (gradient gel 5 to 20%), resulting in a wider separation range. The resolving 
Standard BSA (µl) 1% SDS (µL) Protein mass (µg) 
P0 --- 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
Table VII – Standards used in the BCA protein assay method. Bovine Serum Albumin (BSA) 
solution at 2 mg/ml. SDS, Sodium dodecyl sulfate. 
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gel (Table VIII) was prepared and inserted into the electrophoresis system. After 45 min of 
polymerization at room temperature (RT), the stacking gel (Table VIII) was loaded on the 
top of the resolving gel and left to polymerize, during 30 min at RT. The samples were 
boiled, during 5 min, in loading gel buffer (LB) to allow the protein denaturation. Precision 
plus protein standards Dual Color (BioRad) was used as markers. Proteins were separated 
at 90 mA, during approximately 3 hours in a Hoefer electrophoresis system.  
 
 
(1)Resolving gel percentage used for conditioned media; (2)Resolving gel percentage used for cell lysates. 
3.3.3 – Western Blotting analysis  
 
Western blotting is the technique used for detection of specific proteins in complex 
samples, such as cell culture supernatants, cell lysates, or body fluids. In this technique, the 
proteins separated by electrophoresis are transferred to a solid membrane by the 
application of an electrophoretic field.  
The sandwich was prepared with the gel, nitrocellulose membrane, 3 MM paper, 
two porous pad and two plastic supports. Then, the proteins were transferred at 200 mA for 
at least 16 hours. Finally, the membrane was removed from the sandwich and allowed to 
dry at RT. 
Reagents 
Stacking gel Resolving gel 
3.5% 7.5% (1) 5% (2) 20% (2) 
Water 13.83 mL 33.42 mL 18.65 mL 7.2 mL 
Acrylamide (29:1) 1.75 mL 11.25 mL 3.75 mL 15 mL 
LGB (4X) --- 15 mL 7.5 mL 7.5 mL 
UGB (5X) 4 mL --- --- --- 
10% SDS 200 µL --- --- --- 
10% APS 200 µL 300 µL 150 µL 150 µL 
TEMED 20 µL 30 µL 15 L 16 L 
Table VIII – Stacking and resolving gels compositions (for one SDS-PAGE system, with 1.5 mm 
of thickness). LGB: Lower Gel Buffer; UGB: Upper Gel Buffer; SDS: Sodium dodecyl sulfate; 
APS: Ammonium persulfate; and TEMED: Tetramethylethylenediamine. 
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This is a fast and efficient procedure that preserves the high-resolution separation of 
proteins by SDS-PAGE. Once at the membrane, proteins are suitable to detection by total 
protein staining or to label the proteins of the interest with specific antibodies (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To detect the interest proteins by immunological and chemiluminescent protein 
detection were used a diversity of antibodies (Table IX and Figure 10). 
The nitrocellulose membrane was hydrated with 1x TBS, during 5 min and blocked 
with 5% BSA in 1x TBS-T solution. This step ensures the blocking of possible non-
specific binding-sites. After, membrane was incubated with an unlabeled primary antibody, 
directed against the target protein during 4 hours, with agitation at RT, following by an 
overnight (O.N.) incubation at 4ºC. The membrane was then washed with 1x TBS-T (3 
times, 10 min each) and incubated with the secondary antibody, coupled with horseradish 
peroxidase (HRP) for 2 hours. Three additional washes were performed with 1x TBS-T 
before protein detection with the enhance chemiluminescence (ECL) reagent. This method 
is based on the oxidation of the cyclic diacylhydrazide luminal that results in light 
emission. 
Figure 10 – Schematic illustration of the western blotting technique with indirect detection 
system using Enhanced Chemioluminescence (ECL). Proteins were separated using gel 
electrophoresis, transferred to a membrane and detected using labeled antibodies (adapted from 
[94]). 
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The membrane was incubated with the working mixture of chemiluminescent 
detection reagent (home-made ECL), during 1 minute, or with Luminata Crescendo for 5 
min depending on the protein of interest (Table IX). The membrane was then exposed to 
autoradiography films (Kodak) in an X-ray film cassette. Films were exposed for different 
periods of time in order to optimize the signal, then developed and fixed with the 
appropriate solutions. 
 
 
 
 
 
Protein 1st Antibody Species reactivity 2nd Antibody 
Detection 
method 
APP  
C-Terminal 
Rabbit anti-APP. 
Dilution 1:1000 
(Invitrogen) 
Human, mouse, 
pig, rat 
Peroxidase labeled 
anti-rabbit. Dilution 
1:5000 (Amersham 
Pharmacia) 
LuminataTM 
Crescendo 
sAPP 
Mouse anti-APP 
(N-Terminal 
22C11). 
Dilution 1:250 
(Boehringer) 
Rat, human, 
monkey 
Peroxidase labeled 
anti-mouse. Dilution 
1:5000 (Amersham 
Pharmacia) 
LuminataTM 
Crescendo 
tau5 
Mouse anti-Tau, 
clone tau-5 
Dilution 1:500 
(Millipore) 
Bovine, human, 
mouse, rat, sheep 
Peroxidase labeled 
anti-mouse. Dilution 
1:5000 (Amersham 
Pharmacia) 
ECL 
p-tau (Ser396) 
Rabbit anti-Tau 
(Phospho S396). 
Dilution 1:5000 
(Abcam) 
Mouse, rat, human 
Peroxidase labeled 
anti-rabbit. Dilution 
1:5000 (Amersham 
Pharmacia) 
LuminataTM 
Crescendo 
Table IX – Antibodies used to detect the proteins of interest and their detection methods. 
APP: Amyloid Precursor Protein; sAPP: soluble fragment APP; p-tau: phosphorylated tau. 
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3.3.3.1 – Membrane stripping 
 
To visualized different proteins with similar molecular weight (KDa), the blots were 
striped as following. First, a stripping solution PH 6.7 (contained Tris Base and SDS) was 
prepared and mixed with β-Mercaptoethanol. The nitrocellulose membranes were hydrated 
with 1x TBS and exposures to stripping solution, previously prepared, at 37ºC for 30 min 
with agitation. After, the stripping solution was discarded and the membranes washed 3 
times with 1x TBS-T. Finally, membranes were washed with distillated water and dried at 
RT.  
To confirm the stripping, membranes were rehydrated with 1x TBS and blocked 
with 5% BSA in 1x TBS-T solution, by 1 hour. Then, an incubation with the last used 
secondary antibody was made and the membranes developed with ECL reagent, Luminata 
Crescendo. 
3.3.3.2 – Ponceau S staining 
 
The nitrocellulose membrane was incubated in Ponceau S solution, during 5 min and 
washed with deionized water to make the bands visible. Then, the membrane was scanned 
in a GS-800 calibrated imaging densitometer and extensively washed with 1x TBS-T and 
deionized water to remove the staining. A region of the membrane was used as loading 
control. 
3.3.3.3 – Quantitative analysis 
 
The ImageLab software version 5.1 (BioRad) was used to quantify band intensities of the 
immunoblots and the Ponceau S staining.  
 
3.4 – Statistical analysis 
The software used for the statistical analysis was the GraphPad Prism version 4.0. Data 
was expressed as means ± S.D of three independent experiments (n).  
Statistical significance analysis was conducted by ANOVA followed by Dunnett’s 
test for multiple comparisons, where P < 0.05 was considered significant. 
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3.5 – Immunocytochemistry 
The immunocytochemistry technique allows to detect and localize the antigens of interest 
in cells and tissues, using specific antibodies conjugated with a fluorophore. 
Immunocytochemistry was performed to visualize the apoptotic nuclei as well as to 
detect the cytoskeletal proteins, namely acetylated α-tubulin and F-actin. Cells cultured on 
coverslips (15 mm) at a density of 1x105 cells/well were fixed with 4% PFA for 20 minutes 
at RT. The fixing reagent was removed and cells were washed three times with 1x PBS. 
After, cells were permeabilized with 0.2% PBS-Triton for 10 minutes, washed three times 
with 1x PBS, and then blocked with 3% BSA in PBS for 1 hour at RT. At this stage, cells 
were also washed three times with 1x PBS.  
The cells were then incubated with primary antibody for acetylated α-tubulin diluted in the 
blocking solution (1:250), during 2 hours, in humidified conditions.  Cells were washed 
three times with 1x PBS and then incubated with the appropriate fluorescently-labelled 
secondary antibodies (Alexa Fluor 488, 1:300) in PBS with 0,3% BSA. In order to 
visualize F-actin, Alexa Fluor 568 Phalloidin was diluted (1:1000) in PBS with 0.3% BSA 
and added to coverslips for 1 hour in the dark at RT. Coverslips were further washed three 
times with 1x PBS and one time with distillated water. After, a drop of mounting medium 
(Vectashield with DAPI) was added to each slide for nuclei staining.  
Fluorescence microscopy was performed using an IX81 Motorized Inverted 
Microscope (Olympus Corporation, Hamburg, Germany) equipped with an LCPlanFl 
20x/0.40 objective lens. The analySIS 3.2 software (Olympus) was used for image 
acquisition of around 100 cells/condition and the ImageJ with a custom macro (Figure 11), 
to count the total nuclei. Apoptotic nuclei were counted manually and their percentage 
determined [(apoptotic nuclei/ total nuclei) * 100]. 
 
 
 
 
 
 
 
run("8'bit");-
run("Unsharp-Mask...",-"radius=10-mask=0.90");-
run("Median...",-"radius=3");-
run("Subtract-Background...",-"rolling=50");-
setAutoThreshold("Default-dark");-
run("Threshold...");-
setThreshold(40,-255);-
setOpMon("BlackBackground",-false);-
run("Convert-to-Mask");-
run("Make-Binary");-
run("Fill-Holes");-
run("Watershed");-
run("Set-Measurements...",-"area-redirect=None-decimal=3");-
run("Analyze-ParMcles...”,"size=100'Inﬁnity-show=[Overlay-Outlines]-display-clear-summarize-in_situ");-
1-
2-
3-
4-
5-
6-
7-
8-
9-
10-
11-
12-
13-
14-
Figure 11 – List of commands contained in the ImageJ macro to count the total nuclei number. 
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LSM510 – Meta Confocal Microscope (Zeiss) with 63x/1.4 oil immersion objective 
and the Zeiss LSM510 4.0 software were used to visualize the cytoskeletal proteins. The 
argon laser lines of 405 nm, 488 nm, and a 561 nm DPSS laser were the wavelengths 
selected to acquire the confocal images.  
In both cases, the setting used were the same for each condition and for each 
independent experiment (n). 
  
 
 
 
 
 
4 – Results 
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4 – Results 
 
4.1 – Evaluation of IL-8 and MCP-1 cytotoxicity 
Inflammation is a key event in AD pathogenesis. Several inflammatory mediators have 
been shown altered in AD patients. Chronic inflammation can result in subsequent 
apoptosis and contribute to neurodegeneration typical of AD. To date little is known about 
chemokines in particular MCP-1 and IL-8 on AD. Hence the first step of this thesis was to 
determine the impact of these chemokines on cell toxicity. For that SH-SY5Y 
neuroblastoma cells were differentiated with retinoic acid (RA) and incubated with 
different concentrations of IL-8 and MCP-1 at different time periods, as explained in the 
sections 3.1.1 and 3.1.2, respectively. Following the differentiation period, cell 
morphological alterations were visible, e.g. long extensions (Figure 11A). Microtubule-
associated protein 2 (MAP-2) and β3-tubulin were also used as markers of cell 
differentiation (data not shown). SH-SY5Y cellular viability was measured using the MTT 
assay. Cells were incubated in free serum culture medium with MTT (Cf = 0.5 mg/ml) 
during 4 hours at 37ºC, and the precipitates (dark purple) resulting from mitochondrial 
reduction of MTT to formazan, dissolved with DMSO, and absorbance read at 570 nm. 
Since reduction of MTT can only occur in metabolically active cells, the level of activity 
served as a measure of cell viability. Experiments carried out showed that cells exposed to 
IL-8 during 48 hours, exhibited more dead cells floating in the culture medium, when 
compared with untreated control cells (Figure 11E). Despite that, cells were not 
significantly affected, as observed even for the higher concentration, 150 ng/mL. 
Interestingly, a significant increase (approximately 25%) could be observed for the 10 
ng/mL concentration (Figure 11F). 
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Similar data were obtained when cells were incubated with MCP-1 at different 
concentrations for 24 hours. The appearance of the SH-SY5Y cells after incubation with 
MCP-1 at 150 ng/mL resembles to the one seen for IL-8 at 150 ng/mL, with some round 
and dead cells floating in the culture medium (Figure 12E). However, no significant 
Figure 11 – IL-8 induced cytotoxicity in SH-SY5Y differentiated cells. Untreated control cells  
(A) and cells incubated with IL-8 during 48 hours, at 10 (B), 50 (C), 100 (D) and 150 (E) ng/mL. 
At higher concentrations, such as 150 ng/mL, it is possible to visualize more dead cells (black 
arrows) floating in the culture medium. A magnification of 200x is shown. (F) IL-8 effects in 
cellular viability. Cell viability was measured for the incubation of 48 hours, using the MTT assay 
and the results were expressed as % of control. An increase with statistical significance was 
observed for the concentration of 10 ng/mL, with *P<0.05 by Dunnett’s test. All values are 
expressed as mean ± SD from three independent experiments. 
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differences were observed for the cellular viability when cells were incubated with MCP-1. 
Only a slight decrease in the percentage of viable cells for the higher concentration of the 
MCP-1, could be observed (around 10% bellow control cells), Figure 12F. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – MCP-1 cytotoxic effects in SH-SY5Y differentiated cells. (A) Untreated control 
cells and cells incubated with MCP-1 during 24 hours, at 10 (B), 50 (C), 100 (D) and 150 (E) 
ng/mL, seen at a magnification of 200x. For the higher concentration (150 ng/mL) more rounded 
and dead cells (black arrows) were visualized. (F) MCP-1 effects in cellular viability. Cell 
viability was measured for the incubation of 24 hours, using the MTT assay and the results were 
expressed as % of control. For the MCP-1 at 150 ng/mL lower cell viability relative to control was 
seen. All values are expressed as mean ± SD from three independent experiments. 
2 4  h o u r s
M C P -1  (n g /m L )
C
el
l 
V
ia
b
il
it
y
 (
%
 o
f 
co
n
tr
o
l)
C 1 0 5 0 1 0 0 1 5 0
0
5 0
1 0 0
1 5 0
2 0 0
F 
 A Ctrl 24h  B MCP-1 10 ng/mL  C MCP-1 50 ng/mL 
D MCP-1 100 ng/mL  E MCP-1 150 ng/mL 
44 | P a g e    4  –  R e s u l t s  
Master’s degree thesis  Catarina Domingues 
In parallel, the cytotoxic effects of the chemokines were further addressed using 
immunofluorescent studies. Differentiated SH-SY5Y were exposed to IL-8 and MCP-1, 
and cell nuclei stained as described in section 3.5 to evaluate apoptosis. The nuclei were 
stained with DAPI, which binds strongly to A-T rich regions in DNA emitting blue 
fluorescence. An ImageJ macro was developed to count the nuclei in each of the acquired 
images by fluorescence microscopy. Consistently with MTT data, no significant 
differences could be detected in IL-8 treated cells, when compared with the untreated 
control cells. However, a tendency to increase in the number of apoptotic nuclei was 
observed at the higher IL-8 concentration for the longer period, but not statistically 
significant (Figure 13F).  
During apoptosis, the chromatin suffers a change from a heterogeneous and 
genetically active network, to an inert highly condensed form whose fragments are 
packaged into apoptotic bodies [95]. Membrane blebbing (Figure 13E), which occurs due 
to a contractile force generated by actin-myosin cytoskeletal structures [96] and cell 
shrinkage (Figure 14E), are typical features of apoptotic cells both observed in IL-8 and 
MCP-1 treated cells. 
Relatively to the cells incubated with MCP-1 for 24 hours, differences can be 
observed regarding to percentage of apoptotic nuclei. It was obtained a significant increase 
in about 5% of apoptosis for the concentration of 150 ng/mL, when compared with the 
control cells, as seen in the Figure 14F. 
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Figure 13 – IL-8 apoptotic effects on differentiated SH-SY5Y cells. Apoptotic nuclei 
fluorescence images (A-E) and the respective number obtained for each concentration at 48 hours 
(F). Differentiated untreated control cells (A) and cells incubated with IL-8 at 10 (B), 50 (C), 100 
(D) and 150 (E) ng/mL. In A and E is shown a zoomed image where it is possible to visualize 
normal and apoptotic nuclei, respectively. A magnification of 200x was used during the image 
acquisition and to each condition, the apoptotic nuclei relatively to total nuclei (% of the apoptotic 
nuclei) was determined. All values are expressed as mean ± SD from three independent 
experiments. 
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In summary, and under the conditions tested both IL-8 and MCP-1 chemokines had 
little effects on MTT viability and apoptosis in SH-SY5Y differentiated cell line. 
Figure 14 – MCP-1 apoptotic effects on differentiated SH-SY5Y cells. Apoptotic nuclei 
fluorescence images (A-E) and the respective count obtained for each concentration at 24 hours 
(F). Differentiated untreated control cells (A) and cells incubated with MCP-1 at 10 (B), 50 (C), 
100 (D) and 150 (E) ng/mL, observed at a 200x magnification. In A and E is shown a zoomed 
image where it is possible to visualize normal and apoptotic nuclei, respectively. To each 
condition, the apoptotic nuclei relatively to total nuclei (% of the apoptotic nuclei) was determined 
and for MCP-1 at 150 ng/mL, a statistically significant increase in the apoptotic nuclei number 
was observed, when compared with the untreated control cells, with **P<0.01 by Dunnett’s test. 
All values are expressed as mean ± SD from three independent experiments. 
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4.2 – IL-8 and MCP-1 effects on APP processing 
To date, few studies had focused on the effects of chemokines on APP processing and Aβ 
production, and in particular, little is known about IL-8 and MCP-1 effects on APP 
processing. 
In order to evaluate how these chemokines affect APP processing, differentiated 
neuroblastoma cells were treated with IL-8 at different concentrations (10, 50, 100, 150 
ng/mL) for 24 and 48 hours. After the appropriated incubation period, cell lysates and 
conditioned media were collected and respectively probed with specific antibodies for the 
protein of interest. The rabbit polyclonal antibody anti-APP (APP C-Terminal) was used to 
detect full-length APP in the cell lysates, and the mouse monoclonal anti-APP (22C11, N-
Terminal) was used to recognize the APP N-terminal fragments (sAPP) in the conditioned 
medium. 
Upon IL-8 incubation for 24 and 48 hours, no significant differences could be 
detected for APP levels and sAPP fragment (Figure 15). Despite that, in both cases at 48 
hours a tendency to increase relatively to the shorter incubation period could be observed 
(Figure 15). 
Figure 15 – IL-8 effects on APP processing on differentiated SH-SY5Y cells. Cells were 
differentiated and treated with IL-8 during 24 and 48 hours after which, cell lysates and conditioned 
media were collected and probed with APP C-Terminal (A) and APP N-Terminal 22C11 (B) 
antibodies. Quantification of APP levels by densitometric scanning was normalized to protein 
levels determined by Ponceau S staining. All values are expressed as mean ± SD from three 
independent experiments. 
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For MCP-1 chemokine, again a tendency to increase for APP C-Terminal could be 
detected after 6 hours of incubation, however at 24 hours, for the APP levels no differences 
could be observed (Figure 16A). These results were accompanied by no significant 
variations on sAPP secretion, as detected by the APP N-Terminal 22C11 antibody (Figure 
16B). 
 
 
 
 
 
 
Figure 16 – MCP-1 effects on APP processing on differentiated SH-SY5Y cells. Cells were 
differentiated and treated with MCP-1 during 6 and 24 hours and then, cell lysates and conditioned 
media were collected and probed with APP C-Terminal (A) and APP N-Terminal 22C11 (B) 
antibodies respectively. Quantification of APP levels obtained by densitometric scanning was 
normalized to protein levels determined by Ponceau S staining. Since the sAPP levels were 
difficult to detect at 6 hours of incubation, only the results for the 24 hours are shown. All values 
are expressed as mean ± SD from three independent experiments. 
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Similar data were obtained for undifferentiated SH-SY5Y cells (Figure 17). 
 
Taken together, and although some tendency to increase could be observed, data 
suggests that these chemokines had no significant impact on APP processing in SH-SY5Y 
differentiated cells. 
4.3 – Impact of the chemokines on tau and other cytoskeleton-associated 
proteins 
As mentioned, Alzheimer’s disease pathogenesis is associated with changes at the 
cytoskeletal level, namely on tau protein, a cytoskeletal protein than can be 
hyperphosphorylated and lead to NFT formation, a typical AD hallmark. Hence, the effects 
on tau and on its phosphorylated state were evaluated. 
 Differentiated SH-SY5Y cells were incubated with IL-8 and MCP-1 at 10, 50, 100 
and 150 ng/mL, during 48 and 24 hours respectively. Cell lysates were collected and 
probed for t-tau and p-tau, in particular the Ser396 residue. 
Figure 17 – IL-8 effects on APP processing. After Il-8 treatment during 24 and 48 hours, SH-
SY5Y cell lysates and conditioned media were collected and probed with APP C-Terminal (A) and 
APP N-Terminal 22C11(B) antibody. Quantification of APP levels by densitometric scanning was 
normalized to protein levels determined by Ponceau S staining. All values are expressed as mean ± 
SD from three independent experiments. 
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 As indicated in Figure 18A, when differentiated SH-SY5Y cells were incubated 
with increasing concentration of IL-8 the levels of t-tau detected with the Tau5 antibody 
did not fluctuate markedly. In contrast at the concentration of 150 ng/mL an increase in the 
p-tau (Ser396) was detected. In order to have a comparable term of tau phosphorylated 
state in response to IL-8, the ratio of p-tau (Ser396) versus t-tau was calculated. A 
tendency to increase in p-tau could be observed on particular for the 150 ng/mL of IL-8 by 
approximately 1.2 fold (Figure 18A). 
 Relatively to MCP-1 (Figure 18B) similar data was obtained with the observation 
of 1.4 fold increase on t-tau versus p-tau (Ser396) ratio at 100 ng/mL. This increase was 
not sustained at the highest MCP-1 concentration when compared to control cells.  
 
Figure 18 – Chemokines impact on tau phosphorylation. P-tau/Tau-5 ratio after SH-SY5Y cells 
differentiation and treatment with IL-8 for 48 hours (A) and MCP-1 for 24 hours (B). Cell lysates 
were collected and probed with p-tau (Ser396) and Tau-5 antibodies. Graphs depict tau 
phosphorylated levels at the Ser396 residue with values normalized for t-tau (Tau5) content. All 
values are expressed as mean ± SD from three independent experiments. 
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 The effects of these chemokines on cytoskeleton were further explored by 
evaluating the impact of IL-8 and MCP-1 on actin and tubulin networks. In particular, F-
actin polymerization and α-tubulin acetylation in the presence or absence of these 
chemokines were monitored. Under control conditions, some actin fibres could be 
observed but this appeared shorter and thinner when compared to IL-8 treated cells. In 
contrast, for MCP-1 there was a decrease on F-actin filaments comparatively to control 
cells (Figure 19). Of note, for both chemokines an increase on α-tubulin acetylation at the 
highest concentration (150 ng/mL) was observed, compared to untreated control cells 
(Figure 19). 
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Figure 19 – The effects of chemokines on cytoskeleton network. Upon differentiation and 
chemokine treatments, SH-SY5Y cells were stained and both actin and tubulin networks 
evaluated. Two antibodies were used to stain the cells: Alexa Fluor 568 conjugated phallotoxin 
solution (labelled filamentous F-actin) and acetylated α-tubulin antibody with fluorescently-
labelled secondary antibody (Alexa Fluor 488). The nuclei were stained with DAPI and during 
image acquisition, a 63x/1.4 oil immersion objective was used. Images were acquired using a 
LSM510 - Meta Confocal Microscope. 
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 Overall, our data indicate that under the conditions tested, MCP-1 and IL-8 had 
impact on cytoskeleton network. However additional studies are needed to clarify these 
effects and to unveil the underlying molecular mechanisms. 
 
 
 
 
  
 
 
 
 
 
5 – Discussion 
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5 – Discussion 
 
Alzheimer’s disease is the most common type of dementia, characterized by progressive 
cognitive decline, usually beginning with impairment in the ability to form recent 
memories and then, affecting all intellectual functions, leading to premature death. 
The inflammatory process plays an important role in AD pathogenesis, with signs 
of chronic neuroinflammation and altered levels of some cytokines being linked to the 
disease. The presence of inflammatory molecules is likely to be a very early event in AD 
pathogenesis, preceding the clinical onset of the disease. Many studies have focused on the 
potential of the inflammatory molecules as candidate biomarkers for AD diagnosis, 
however many of these data are still controversial and inconclusive. This work aimed to 
contribute to the understanding of the role of chemokines, such as IL-8 and MCP-1 on AD. 
Namely, this study addressed their apoptotic properties and impact on APP and tau, two 
key proteins in AD pathogenesis. 
IL-8 and MCP-1 cytotoxicity  
According to Thirumangalakudi et al [91], IL-8 may have two distinct effects on neuronal 
cells associated with a dose-dependent manner. At higher concentrations of this chemokine 
there was a significant decrease in cell survival. Nevertheless, at low concentrations IL-8 
appears to have a neurotrophic effect, registering its peak at 10 ng/mL with a registered 
survival of 120%. This data is consistent with our own results, where at a concentration of 
10 ng/mL IL-8 leads to a 25% of cell viability, as determined by MTT (Figure 11). No 
significant decrease of cell viability or apoptosis was observed for this chemokine, under 
the tested conditions (Figure 13). Despite that, the same study [91] reported that neuronal 
exposure to IL-8, leads to a dose-dependent expression of Bim, implicating this protein as 
an important mediator of the IL-8 neuronal cell death cascade. 
  With respect to the MCP-1 and its cytotoxicity, a more evident decrease to 
approximately 90% of viable cells was obtained, mainly at the concentration of 150 ng/mL 
(Figure 12). Yamamoto et al [88] tested the effects of MCP-1 in PC12 cells on Aβ 
concentration, when cells were treated for 24 hours. Data showed a decrease in this peptide 
at the 10 ng/mL concentration of MCP-1. This may correlate with the increase in cell 
survival verified in our experiments for the same concentration. 
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Regarding to the results obtained for the apoptosis, a significant difference was 
detected in the number of apoptotic nuclei for the highest MCP-1 concentration (150 
ng/mL). This points in the same direction as the MTT assay, where lower cell viability 
corresponds to a high number of apoptotic nuclei.  
Yang et al [97] reported that in a neuron/microglia co-culture with a previous 
induced damage, the addition of MCP-1 increment the neuronal death. It is known that 
under an inflammatory response, microglia is activated and releases some inflammatory 
mediators, in which MCP-1 is included. MCP-1 release may affect neuronal cells viability 
and death contributing to AD neurodegeneration. 
IL-8 and MCP-1 on APP  
Additional studies were directed for the effects of MCP-1 and IL-8 on both APP and tau. 
These two proteins are in the basis of Aβ production or NFT formation. 
IL-8 is a chemokine produced by macrophages in the presence of the Aβ peptide 
[48], being important for activated microglia recruitment to the sites of the damaged brain. 
To date, there is no information about the IL-8 effects on APP processing and Aβ 
production. This work focused on the evaluation of the IL-8 effects on APP itself and on 
sAPP secretion, in a neuronal model of SH-SY5Y differentiated cells. No significant 
differences were detected in APP levels, although for the longer period a tendency to 
increase on sAPP secretion and APP were observed, when compared to the shorter 
incubation period (Figure 15).  
 MCP-1 is a chemokine produced by microglial cells and stimulates astrocytes, 
which together can participate in the degradation of the Aβ peptide. However, when MCP-
1 is overexpressed, it induces microgliosis and enhances Aβ deposits as well as its uptake 
by the microglia. This uptake promotes the oligomerization of Aβ species in both the 
intracellular and extracellular fractions. Lack of available information for MCP-1 and APP 
processing leads us to focus on this chemokine. 
 Like for IL-8, when SH-SY5Y cells were incubated with MCP-1 no significant 
differences could be observed. Only a marginal increase on full-length APP could be 
detected for the lower incubation period, as well as for the sAPP levels, mainly at the 
highest concentration (150 ng/mL) for 24 hours (Figure 16). 
Although change in the levels of those chemokines have been reported in AD, and 
not excluding other roles of this in the disease, we can suggest that the two tested 
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chemokines produce marginal changes on APP metabolism, based on the data obtained. 
Additional set of experiments only could be carried out to certify the data and minimize the 
SD variation, leading to a more accurate correlation between these chemokines, APP 
processing and the Alzheimer’s disease pathogenesis. 
Chemokines impact on tau and other cytoskeletal proteins 
 Tau is a microtubule-associated protein that helps in the microtubular and 
cytoskeletal stability. Alterations in this protein leads to NFT formation and abnormal 
axonal transport with subsequent energetic and nutritional deficit rendering in neuronal 
death [6]. For IL-8 our experiments revealed a decrease in tau phosphorylation relatively to 
the total tau at the lower concentration, and an increase at the concentration of 150 ng/mL. 
Interestingly the decrease on p-tau correlates with an increase on cell viability for IL-8 at 
10 ng/mL (Figures 18A and 11B). 
 For MCP-1 a tendency to increase on p-tau (Ser396) residue could be observed at 
the higher concentration (Figure 18B). Like for APP processing, no significant differences 
could be observed for these chemokines regarding the phosphorylation of the Ser396 
residue. However other relevant residues in AD perspective, could be addressed, namely 
Ser202 and Ser262 [98] whose phosphorylation are involved in the formation of pre-NFT, 
controlling the microtubule-binding ability as well as the axonal transport regulation 
[99,100]. 
 Many cytoskeletal abnormalities have been reported in AD not only on tau but also 
at the actin and tubulin level [101]. Actin filaments in the cell cortex determine the shape, 
stiffness and the movement of the cell surface. These are highly dynamic proteins, whose 
polymerization is usually correlated with their disassembly [102]. In particular for IL-8 
treated cells, some bundles of actin filaments were seen, which suggests an increase in F-
actin polymerization with possible consequences to the cell dynamic and integrity. 
Tubulin is a protein that composes the cytoskeletal microtubules responsible for the 
cell shape, transport, motility and division. Studies have shown that alterations on tubulin 
acetylation can trigger cell death, possibly linked to the Alzheimer’s disease pathogenesis 
[101,103]. Interestingly, data obtained for both chemokines show an increase in acetylated 
α-tubulin upon cell incubations with IL-8 and MCP-1, that appears to be more marked for 
the last one (Figure 19). Additional studies should be carried out in order to address 
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cytoskeleton signal molecules that could be involved in these effects, for e.g. Rac and 
others. 
 Zhang et al [104], refers that there is a compensatory mechanism between tau 
phosphorylation and α-tubulin acetylation. This occurs when tau stabilizing activity on the 
cytoskeletal microtubules is lost and the α-tubulin acetylation raises to maintain the 
balance. Data obtained for IL-8 is in agreement with this observation, since that with the 
increase of the p-tau (Ser396), an increase in α-tubulin acetylated was detected (Figures 
18A and 19).  
 IL-8 and MCP-1 showed to change the cytoskeleton-proteins dynamics, however 
additional studies can improve knowledge behind mechanisms of these chemokines on 
cytoskeleton networks. 
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Conclusion & Future Perspectives 
IL-8 and MCP-1 are two chemokines known to be altered in AD patients. However the role 
of these chemokines on AD pathogenesis is little explored. The work developed in this 
thesis, reveal that the tested chemokines had little effects on APP and tau, only showing 
marginal increase on apoptosis, APP processing and tau phosphorylation. Interestingly, 
effects on both actin and tubulin networks were observed. Presently it is difficult to 
interpret the data obtained since little is known about the mode of action of these 
chemokines. Complementary studies should be performed, not only to evaluate other APP 
fragments resulting from its processing, such as the Aβ peptide itself, but also to clarify the 
IL-8 and MCP-1 effects on the cytoskeleton-associated proteins. Studies including 
cytoskeleton modulating drugs or specifically addressing signal molecules involved in 
cytoskeletal dynamics, could aid in the understanding of the mechanisms underlying these 
effects. In sum, from the work herein presented, the most prominent effect of these 
chemokines was at the cytoskeletal level. Cytoskeletal alterations have been associated 
with AD pathogenesis by impacting on neuronal dynamics and survival, consequently 
leading to neurodegeneration. 
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7 – Annexes 
 
In this section is listed the equipment and the solutions used for the experiments developed 
in this thesis. 
7.1 – Cell Culture 
 
Equipment: 
• Hera cell CO2 incubator (Heraeus) 
• Safety cabinet Hera safe (Heraeus) 
• Inverted optical microscope (LEICA) 
• Hemacytometer (Sigma) 
• Sonicator (U200S IKA) 
• Bath SBB6 (Grant) 
• Culture Plates (Corning) 
 
Reagents and Solutions: 
• Complete medium 10% FBS MEM:F12 (1:1) 
 
• Differentiation medium 1% FBS MEM:12 (1:1) 
MEM (Gibco, Invitrogen) 4.805 g  
F12 (Gibco, Invitrogen) 5.315 g  
NaHCO3 (Sigma) 1.7 g  
Sodium Pyruvate (Sigma) 0.055 g  
1% Antibiotic/Antimycotic (AA) mix (Gibco, Invitrogen) 10 mL  
10% FBS (Gibco, Invitrogen) 100 mL  
L-Gluatamine (200 mM stock solution) 2.5 mL  
MEM (Gibco, Invitrogen) 4.805 g  
F12 (Gibco, Invitrogen) 5.315 g  
NaHCO3 (Sigma) 1.7 g  
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Adjust to PH 7.4 and to a final volume of 1000 mL in dH2O. Sterilize by filtering through a 
0.2 µm filter and store at 4ºC.  
 
• PBS (1x) 
Dissolve one sack of BupH Modified Dulbecco’s Phosphatase Buffered Saline Pack 
(Pierce) in deionized H2O.  
Final composition: 
Sodium Phospatase 8 mM 
Potassium Phosphatase 2 mM 
Sodium Chloride 140 mM 
Potassium Chloride 10 mM 
 
Sterilize by filtering through a 0.2 µm filter and store at 4ºC. 
 
• RIPA Buffer (Sigma-Aldrich) 
For 6.5 mL of RIPA buffer add: 
NaF 40.3 µL 
NaO 65 µL  
Protease Inhibitor cocktail (Sigma-Aldrich) 65 µL 
 
7.2 – MTT assay 
 
Equipment: 
• Infinite M200 (Tecan) and I-ControlTM software 
 
 
Sodium Pyruvate (Sigma) 0.055 g  
1% Antibiotic/Antimycotic (AA) mix (Gibco, Invitrogen) 10 mL  
1% FBS (Gibco, Invitrogen) 10 mL  
L-Gluatamine (200 mM stock solution) 2.5 mL  
Retinoic Acid (20 mM stock solution) 500 µL 
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Reagents and Solutions: 
• MTT (0.5 mg/mL) (Sigma-Aldrich) 
• DMSO (99.9%) (Fisher Scientific) 
 
7.3 – Protein Content Determination 
 
Equipment: 
• Infinite M200 (Tecan) and I-ControlTM software 
 
 
Reagents and Solutions: 
• BCA assay kit (Pierce, Rockford, IL) 
• Bovine serum albumin (BSA) (Pierce) 
• Working reagent (50 reagent A: 1 Reagent B) 
 
Reagent A: sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.2 N 
sodium hydroxide. 
Reagent B: 4% cupric sulfate. 
 
7.4 – SDS-PAGE 
 
Equipment: 
• Electrophoresis system (Hoefer SE600 vertical unit) 
• Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents and Solutions: 
• Acrylamide (29:1) 
 
• UGB (Upper Gel Buffer) (5x) 
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For 900 mL of deionized H2O add 75.69 g of Tris. Mix until the solute has dissolved. 
Adjust the PH to 6.8 and the volume to 1 L with deionized H2O. 
 
• LGB (Lower Gel Buffer) (4x) 
For 900 mL of deionized H2O add 181.65 g of Tris and 4 g of SDS. Mix until the solute 
has dissolved. Adjust the PH to 6.8 and the volume to 1 L with deionized H2O. 
 
• 10% APS (Ammonium Persulfate) 
In 10 mL of deionized H2O dissolve 1 g of APS. Note: Always use a new APS solution.  
 
 
• 10% SDS (Sodium dodecilsulfate) 
In 10 mL of deionized H2O dissolve 1 g of SDS. 
 
• Loading Gel Buffer (LB) (4x) 
 Tris Solution (PH 6.8) 1mM 2.5 mL (250 mM) 
 SDS 0.8 g (8%) 
 Glicerol 4 mL (40%) 
 Beta-Mercaptoetanol 2 mL (2%) 
 Bromophenol blue 1 mg (0.01%) 
 
Adjust the volume to 10 mL with deionized H2O. Store in the dark at room temperature. 
 
• Tris 1M (PH 6.8) solution  
For 150 mL of deionized H2O add 30.3 g of Tris base. Adjust the PH to 6.8 and the 
final volume to 250 mL. 
 
• Running buffer (10x) 
Tris 30.3 g (250 mM) 
Glycine 144.2 g (2.5 mM)  
SDS 10 g (1%) 
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Dissolve in deionized H2O and adjust the PH to 8.3 and the final volume to 1 L. 
 
7.5 – Western-Blotting 
 
Equipment: 
• Transphor Electrophoresis unit (Hofer TE 42) 
• Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
Reagents and Solutions: 
• Transfer buffer (1x) 
Tris 3.03 g (25 mM) 
Glycine 14.41 g (192 mM)  
Mix until the solutes have dissolved. Adjust the PH to 8.3 with HCL and the final volume 
to 800 mL with deionized H2O. Just before usage add 200 mL of methanol (20%). 
 
7.6 – Immunoblotting 
 
• 10x TBS (Tris Buffered Saline)  
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM)  
 
Adjust the PH to 8.0 with HCL and the final volume to 1 L with deionized H2O. 
 
• 10x TBS-T (TBS-Tween 20) 
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM)  
Twenn 20 5 mL (0.05%) 
 
Adjust the PH to 8.0 with HCL and the final volume to 1 L with deionized H2O. 
 
• Ponceau S solution 
Dissolve 0.1 g of Ponceau S (Sigma) in 100 mL of 5% acetic acid solution (5 mL of acetic 
acid dissolved in 95 mL of deionized H2O). 
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• Blocking solution 
5% of BSA (Bovine serum albumin, NZytech) in 1x TBS-T. 
 
• ECL solutions 
Luminata crescendo (Millipore) 
Home-made ECL 
 
• Developer and fixer solution (Sigma) 
 
• Membrane stripping solution 
Tris-HCL (PH 6.7) 3.76 g (62.5 mM) 
SDS 10 g (2%)  
Beta-mercaptoethanol 3.5 mL (100 mM) 
 
Dissolve Tris and SDS in deionized H2O and adjust the PH to 6.7. Add the 
mercaptoethanol and adjust the final volume to 500 mL. 
 
7.7 – Quantitative analysis 
 
Equipment: 
• GS-710 calibrated imaging densitometer (Bio-Rad). 
 
7.8 – Immunocytochemistry 
 
Equipment: 
• IX81 Motorized Inverted Microscope (Olympus Corporation, Hamburg, Germany) 
and analySIS 3.2 software (Olympus) 
• ImageJ software 
• LSM510 – Meta Confocal Microscope (Zeiss) and Zeiss LSM510 4.0 software 
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Reagents and Solutions: 
• Coverslips (15 mm) (Thermo Scientific) 
• 4% PFA (Sigma) 
For 50 mL of deionized H2O add 4 g of PFA. Mix until the solute has dissolved, at 58ºC. 
Adjust the PH to 6.9 and the final volume to 100 mL with PBS 2x. Filter and store at RT in 
the dark. 
• Permeabilizating solution 
0.2% Triton in 1x PBS. 
• Blocking solution 
3% of BSA (Bovine serum albumin, NZytech) in 1x PBS.  
• Vectashield with DAPI 
• Antibodies 
 
1st Antibodies 2nd Antibody 
Acetylated 
α-Tubulin 
Mouse anti-acetylated α-tubulin, 
clone 6-11B-1 
Dilution 1:250 
(Sigma) 
Alexa Fluor 488  
Dilution 1:300 
(Life Technologies) 
F-Actin 
Alexa Fluor 568 Phalloidin 
Dilution 1:1000  
(Life Technologies) 
 
7.9 – Statistical analysis 
 
Equipment: 
• GraphPad Prism version 4.0 software. 
 
 
 
